MAIN STORY
What the trial numbers actually show
The late-stage findings suggest that izalontamab brengitecan, known as iza-bren, kept cancer from worsening for longer than standard chemotherapy. Progression-free survival measures time until the disease worsens or a patient dies; it is not the same as extending overall life expectancy. Likewise, a 59% relative reduction in the risk of progression or death does not mean that 59% of patients were cured.
Investigators reported tumor responses in 40.5% of patients receiving iza-bren, compared with 20.2% of chemotherapy recipients. The median duration of those responses was 6.9 months versus 4.2 months. Taken together, these figures suggest a meaningful anticancer signal, although treatment choices also depend on symptoms, previous therapies, side effects and patient preferences.
The science behind a targeted payload
Iza-bren is an antibody-drug conjugate, or ADC, designed to combine biological recognition with a cell-killing payload. The investigational compound recognizes two proteins, EGFR and HER3.

















